MajesTEC-1
MajesTEC-1 was the pivotal single-arm study for the first myeloma bispecific, with responses in 63% of patients who had exhausted the main drug classes.
ORR 63%, CR or better 39%; median PFS 11.3 months, median OS 22.2 months at 30-month follow-up. Infections were the leading cause of non-relapse death, prompting IVIG prophylaxis.
- 63 out of 100 people had their tumour shrink with Teclistamab.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Relapsed/refractory myeloma after ≥3 lines: teclistamab monotherapy. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- TrialMajesTEC-3
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, Multiple myeloma.
- PairingCaution: T-cell redirectors and infections
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, Multiple myeloma.
- PairingBCMA-directed therapy → GPRC5D-directed therapy
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, Multiple myeloma.
- PersonSundar Jagannath
Shares Teclistamab, Multiple myeloma.
- InstitutionIUCT Oncopole – Institut Universitaire du Cancer de Toulouse
Shares Teclistamab, Multiple myeloma.
- ProductTalquetamab
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Multiple myeloma.
- ProductElranatamab
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Multiple myeloma.
- Key paperMagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, Multiple myeloma.